The SmartPak™ Pharmacy Equine Product Information Sheet

Phenylbutazone

NOTE: You may be sent an FDA-approved generic drug that may be manufactured by more than one company. Therefore, the product you receive may not always have the same label, color or shape.

How Supplied by SmartPak – Phenylbutazone is available in daily dose SmartPaks. It is also available as 1g tablets in a 100-count bottle, as powder in a 2.2lb container, or as paste in a 6g syringe, a 12g syringe, or an apple-flavored 12g syringe.

Category – Phenylbutazone is a synthetic, nonhormonal, anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions.

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications (Uses) – Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses.

Dosage and Administration – Orally 1 – 2g of Phenylbutazone per 500lb of body weight, not to exceed 4g daily. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response. The response to Phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach. Intermittent treatment given only when signs appear may be indicated. When administering Phenylbutazone paste the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.

Contraindications – Use with caution in patients who have a history of drug allergy.

Human Warnings – Not for use in humans. Keep out of reach of children.

Warning – Not for use in horses intended for food.

Precautions – In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently. Stop medication at the first sign of GI upset, jaundice or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of 2 weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools should be regarded as a signal for immediate cessation of therapy and institution of the appropriate countermeasures.

Storage Conditions:
Store at 59 – 86F.

Rev. 1/08

SmartPak™
40 Grissom Road, Suite 500
Plymouth, MA 02360
Phone: 1-800-431-4194
Fax: 1-800-431-4179
www.SmartPak.com